Published in Antimicrob Agents Chemother on May 23, 2016
New developments in anti-malarial target candidate and product profiles. Malar J (2017) 1.50
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malar J (2016) 0.79
Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects. Br J Clin Pharmacol (2016) 0.78
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis (2017) 0.75
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
The parasite clearance curve. Malar J (2011) 4.30
The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol (1975) 3.80
A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ (1983) 3.31
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA (2014) 2.56
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol (2011) 2.53
Malarial anemia: of mice and men. Blood (2007) 2.27
Designing the next generation of medicines for malaria control and eradication. Malar J (2013) 2.25
Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg (1997) 2.17
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther (1999) 2.16
A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ (1983) 2.10
Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1993) 1.95
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
The role of animal models for research on severe malaria. PLoS Pathog (2012) 1.76
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother (2009) 1.73
Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis (2010) 1.65
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One (2011) 1.47
How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance? Antimicrob Agents Chemother (2015) 1.44
Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence. Cytometry A (2009) 1.41
The relevance of non-human primate and rodent malaria models for humans. Malar J (2011) 1.36
Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat Rev Drug Discov (2015) 1.35
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn (2007) 1.34
A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar J (2011) 1.32
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med (2015) 1.29
Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg (2008) 1.19
Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol (2012) 1.09
Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol (2004) 1.07
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrob Agents Chemother (2015) 0.99
Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar J (2014) 0.87
A new in vivo screening paradigm to accelerate antimalarial drug discovery. PLoS One (2013) 0.86
Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. J Antimicrob Chemother (2014) 0.80
Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis (2015) 1.72
New developments in anti-malarial target candidate and product profiles. Malar J (2017) 1.50
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis (2015) 1.44
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS Pathog (2016) 1.11
Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J Allergy Clin Immunol (2014) 1.08
Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl Trop Dis (2014) 1.01
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrob Agents Chemother (2015) 0.99
Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br J Clin Pharmacol (2015) 0.93
Tools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria? PLoS Biol (2016) 0.93
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. J Infect Dis (2015) 0.84
A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. PLoS Negl Trop Dis (2015) 0.83
Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrob Agents Chemother (2016) 0.83
A chemical susceptibility profile of the Plasmodium falciparum transmission stages by complementary cell-based gametocyte assays. J Antimicrob Chemother (2016) 0.80
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malar J (2016) 0.79
Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects. Br J Clin Pharmacol (2016) 0.78
Improving medication titration in heart failure by embedding a structured medication titration plan. Int J Cardiol (2016) 0.76
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Antimicrob Agents Chemother (2016) 0.76
How to tackle antimalarial resistance? EMBO Mol Med (2016) 0.76
Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol. Antimicrob Agents Chemother (2014) 0.75
Erratum to: New developments in anti-malarial target candidate and product profiles. Malar J (2017) 0.75
Both Intrinsic Substrate Preference and Network Context Contribute to Substrate Selection of Classical Tyrosine Phosphatases. J Biol Chem (2017) 0.75
Diagnosis and Treatment of Plasmodium vivax Malaria. Am J Trop Med Hyg (2016) 0.75
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire. Malar J (2017) 0.75
Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients. Antimicrob Agents Chemother (2015) 0.75
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med (2016) 0.75
malERA: An updated research agenda for malaria elimination and eradication. PLoS Med (2017) 0.75
Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia. PLoS Med (2020) 0.75
Malaria. Nat Rev Dis Prim (2017) 0.75
Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in . Sci Transl Med (2022) 0.75
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers. Am J Trop Med Hyg (2017) 0.75
Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Glob Health (2017) 0.75
Predictors of significant coronary artery disease in atrial fibrillation: Are cardiac troponins a useful measure. Int J Cardiol (2016) 0.75
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med (2017) 0.75
Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS Med (2017) 0.75
Liver Function Test Abnormalities in Experimental and Clinical Infection. Am J Trop Med Hyg (2020) 0.75
Susceptibility Testing of Medically Important Parasites. Clin Microbiol Rev (2017) 0.75